Clinical Trials Logo

Clinical Trial Summary

Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks and how colchicine helps, are questions not yet resolved. Elucidating the role of the inflammatory proteins is an important step towards the understanding of these questions. To date only small numbers of cytokines and inflammatory proteins have been studied individually. We propose to study a large number of these proteins in the RNA and protein levels addressing the interaction between them and the effect of colchicine on their expression.

Blood samples will be drawn from consenting patients in remission, during attacks, under and without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will donate control blood samples for the study. RNA will be produced from the neutrophils, and cytokines and various proteins' RNA expression will be determined. Major expressed proteins will be measured in the same samples and the results will be analyzed with regard to the activity of the disease, MEFV mutations and colchicine treatment status. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.


Clinical Trial Description

Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen). Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks and how colchicine helps, are questions not yet resolved. Elucidating the role of the inflammatory proteins is an important step towards the understanding of these questions. To date only small numbers of cytokines and inflammatory proteins have been studied individually. We propose to study a large number of these proteins in the RNA and protein levels addressing the interaction between them and the effect of colchicine on their expression.

Blood samples will be drawn from consenting patients in remission, during attacks, under and without colchicine treatment. (20 patients in each category).Twenty healthy volunteers will donate control blood samples for the study. RNA will be produced from the neutrophils, and cytokines and various proteins' RNA expression will be determined. Major expressed proteins will be measured in the same samples and the results will be analyzed with regard to the activity of the disease, MEFV mutations and colchicine treatment status. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00323440
Study type Observational
Source Sheba Medical Center
Contact
Status Withdrawn
Phase N/A
Start date August 2008
Completion date August 2016

See also
  Status Clinical Trial Phase
Recruiting NCT00658060 - Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients N/A
Withdrawn NCT05448391 - A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) Phase 2
Recruiting NCT05190991 - Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever Phase 2
Completed NCT00094900 - Interleukin-1 Trap to Treat Autoinflammatory Diseases Phase 2
Not yet recruiting NCT06033339 - Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology N/A
Completed NCT01705756 - Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Phase 3
Recruiting NCT05596643 - Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever
Enrolling by invitation NCT02175589 - Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation Phase 2
Completed NCT05177120 - Central Sensitization in Familial Mediterranean Fever (FMF)
Active, not recruiting NCT06257342 - Physical Abilities of Teenagers With Familial Mediterranean Fever
Recruiting NCT04478409 - Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
Recruiting NCT06034795 - Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever
Completed NCT04729218 - The Movement Imagery Ability in Patients With Familial Mediterranean Fever
Enrolling by invitation NCT01059279 - Heat Intolerance in the Group of FMF Patients
Enrolling by invitation NCT04724993 - Effects of Online Aerobic Exercise Training and Physical Activity Counseling in Juvenile Familial Mediterranean Fever N/A
Completed NCT03747315 - A Diagnostic Test for Familial Mediterranean Fever
Completed NCT01075906 - Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients Phase 1
Completed NCT00582907 - Rilonacept for Treatment of Familial Mediterranean Fever (FMF) Phase 2
Not yet recruiting NCT05488561 - Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings N/A
Recruiting NCT05092776 - Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine Phase 2